Related Experiment Videos
Zoledronic acid (Zometa) use in bone disease
1University of Texas, MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston 77030, USA. rtheriau@mdanderson.org
Expert Review of Anticancer Therapy
|May 2, 2003
Summary
Zoledronic acid, a bisphosphonate, effectively treats bone diseases like osteoporosis and cancer-related bone conditions. It reduces bone breakdown, increases bone density, and improves outcomes for cancer patients with bone metastases.
Area of Science:
- Pharmacology and Bone Biology
- Oncology
- Clinical Therapeutics
Background:
- Zoledronic acid is a potent bisphosphonate with observed clinical benefits in metabolic and cancer-related bone diseases.
- Preclinical models suggest zoledronic acid possesses anticancer properties beyond its antiosteoclast activity.
Purpose of the Study:
- To evaluate the efficacy of zoledronic acid in various bone conditions, including osteoporosis, Paget's disease, and bone metastases.
- To assess the antiosteoclast and anticancer effects of zoledronic acid in clinical settings.
Main Methods:
- Randomized, double-blind clinical trials were conducted.
- Evaluations included measurements of bone turnover markers (N-telopeptide, C-telopeptide, deoxypyridinoline) and bone mineral density (dual energy x-ray absorptometry).
- Clinical benefits in cancer patients were assessed by bone pain, skeletal events, and time to first skeletal event.
Main Results:
- Zoledronic acid demonstrated significant antiosteoclast activity, evidenced by reduced bone breakdown markers.
- Bone mineral density increased in postmenopausal osteoporosis patients treated with zoledronic acid.
- In cancer patients, zoledronic acid improved bone pain, reduced skeletal events, and delayed their onset.
Conclusions:
- Zoledronic acid is effective in managing osteoporosis and Paget's disease of bone.
- The drug provides significant clinical benefits for patients with bone metastases from various cancers, including multiple myeloma, breast, lung, and prostate cancer.